Navigation Links
Avid Announces Results of AV-1 Molecular Imaging Agent for,Alzheimer's Disease Presented at AD/PD Meeting

PHILADELPHIA--(BUSINESS WIRE)--Mar 19, 2007 - Avid Radiopharmaceuticals, Inc. (Avid), a product-focused molecular imaging company, today announced the presentation of the first results from a clinical study of 18F-AV-1/ZK (AV-1), a novel radiopharmaceutical for positron emission tomography (PET) imaging of amyloid plaques in patients with Alzheimer's disease. Principal investigator Dr. Christopher Rowe from Austin Hospital of Melbourne, a leading investigator in the field of molecular imaging of Alzheimer's disease, presented the results at the 8th International Conference on AD/PD in Salzburg, Austria.

The goal of this first clinical study was to examine whether PET imaging with AV-1 could be used to distinguish patients with Alzheimer's disease from those with normal cognitive function. AV-1 binds avidly to B-amyloid, the chief constituent of amyloid plaques, which accumulates abnormally in the brains of people with Alzheimer's disease.

Dr. Rowe reported that PET imaging with AV-1 clearly distinguishes AD from healthy elderly subjects, and may be used to quantify amyloid burden. AV-1 PET scans showed high levels of signal in the Alzheimer's patients, particularly in areas of the brain known to contain amyloid plaques. In contrast there was no retention of AV-1 in the cerebellar cortex, an area where amyloid plaques do not accumulate.

This is the first scientific report of a clinical trial with an 18F-compound designed for specifically imaging amyloid plaques in AD. The wide availability of 18F allows for the possibility of amyloid imaging at a large number of clinical sites worldwide.

"We are extremely encouraged by the results of this clinical study with Avid's first compound, AV-1. These data have provided the rationale for Avid's next generation compounds for amyloid imaging, which are now in clinical trials in the United States," said Daniel Skovronsky, MD, PhD, CEO of Avid.

AV
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:7/29/2015)... July 29, 2015  Cepheid (Nasdaq: CPHD ... update to Xpert® Carba-R, with the addition of ... The on-demand, molecular test also detects and differentiates ... resistance, namely KPC, NDM, VIM, IMP-1 and OXA-48. ... CROs or Superbugs, are a growing and expensive ...
(Date:7/29/2015)... MOUNTAIN VIEW, Calif. , July 29, 2015 /PRNewswire/ ... in the growth strategy of pharmaceutical firms in ... . The realization is that an effective working ... sales, pricing pressures and patent cliffs. Big pharma companies ... bolster returns. Logo - http://photos.prnewswire.com/prnh/20150724/241957LOGO ...
(Date:7/29/2015)... , July 29, 2015 ... Therapeutic Vaccines Market - Growth, Trends & Forecasts (2015-2020) ... expected to be worth US$ 2.85 billion by the ... being the largest market globally accounting for more ... market for Therapeutic Vaccines is expected to grow at ...
Breaking Medicine Technology:'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 2'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 3'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms 4Working Capital Management Seizes Priority in North American and European Pharma Industry 2Working Capital Management Seizes Priority in North American and European Pharma Industry 3Working Capital Management Seizes Priority in North American and European Pharma Industry 4New Approaches and Technical Advances by Major Players Like Novartis, Merck KGaA, Pfizer, GlaxoSmithKline and Others to Elevate the Global Therapeutic Vaccines Market 2New Approaches and Technical Advances by Major Players Like Novartis, Merck KGaA, Pfizer, GlaxoSmithKline and Others to Elevate the Global Therapeutic Vaccines Market 3
... Leader Ventures, an investment firm offering blended debt and ... Inc., an innovative drug discovery company. ... co-founders Stig K. Hansen and Daniel A. Erlanson while ... candidates in a broad range of therapeutic areas. ...
... 20, 2010 Valeant Pharmaceuticals International, Inc. (NYSE: ... W. Loberg, Valeant,s former senior vice president and corporate ... chief financial officer, effective immediately, replacing Peggy Mulligan, former ... order to pursue other interests.  The Company has initiated ...
Cached Medicine Technology:Leader Ventures Supports Innovative Drug Discovery Company Carmot 2Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO 2Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO 3
(Date:7/29/2015)... ... July 29, 2015 , ... Employee Fiduciary, LLC announces the ... general contact information, website, types of plans administered, years in business, and credentials of ... have at least one plan with Employee Fiduciary. A search can be done by ...
(Date:7/29/2015)... ... ... TransFlip is an all new dynamic transition pack for FCPX, containing flipping ... are easy to apply and modify for any skill-level user. TransFlip includes custom bounce ... kinetic flipping panel animations are just a few clicks away. , TransFlip contains over ...
(Date:7/29/2015)... ... July 29, 2015 , ... Toronto native Douglas James ... Dr. Cottrell has been making predictions about the economy, politics, social issues, as ... these prognostications. He warns that extreme weather conditions and increased earthquake / volcanic ...
(Date:7/29/2015)... ... July 29, 2015 , ... The Woodlands and Spring Fit Body ... donating to worthy charitable causes each month. The new system will track each time ... each Check In at each facility, the boot camps will donate 20 cents to ...
(Date:7/29/2015)... Hoffman Estates, IL (PRWEB) , ... July 29, 2015 , ... ... can both benefit from two new products on Mercola.com: a vertical “garden tower” and ... – which can be squeezed into small corners on a porch, balcony, or rooftop ...
Breaking Medicine News(10 mins):Health News:Employee Fiduciary Launches Financial Advisor Directory 2Health News:Pixel Film Studios Releases FCPX Transition TransFlip for FCPX 2Health News:Author Warns Public to Prepare for Imminent Environmental Disaster 2Health News:Transforming Texan Lives and Bodies: Woodlands and Spring Fitness Boot Camps Commit to Multiple Charity Donations 2Health News:Transforming Texan Lives and Bodies: Woodlands and Spring Fitness Boot Camps Commit to Multiple Charity Donations 3Health News:Mercola.com Introduces NEW Garden Tower and Enhanced Mineral Solution for Healthy Plants 2
... chronic myeloid leukemia patients who are out of treatment options ... their cancer cells have a mutation that makes them resistant ... of the American Society of Hematology. In a Phase ... hematologic responses (absence of CML cells in the blood) and ...
... inhibitors are substantially improving treatment of myelofibrosis ( ... http://www.mayoclinic.org/ ) researchers who are presenting results of ... of the American Society of Hematology ( http://www.hematology.org/ ... VIDEO ALERT: Additional audio and video resources, including ...
... Texas AgriLife Research engineers has developed a way to cut ... to kill 99.999 percent of salmonella, E. coli ... in a Mylar bag filled with pure oxygen, Dr. Carmen ... they could significantly reduce the amount of radiation needed to ...
... HealthDay Reporter , SUNDAY, Dec. 5 (HealthDay ... they managed to "correct" a malfunctioning gene responsible for ... leads to prolonged bleeding from even minor hits or ... cancers and dangerous infections. However, one of the ...
... Reporter , SATURDAY, Dec. 4 (HealthDay News) -- A new ... safer treatment for patients coping with deep-vein thrombosis (DVT), a ... published online Dec. 4 in the New England Journal ... for these potentially life-threatening clots, which most typically form ...
... Quigley will describe a promising new approach to blocking ... meeting in Orlando, Fla. Quigley will speak at ... at the Orange County Convention Center, 9800 International Drive, ... the Human Erythroid Heme Exporter, FLVCR, Export Heme: Potential ...
Cached Medicine News:Health News:Phase I trial indicates ponatinib may thwart most resistant CML 2Health News:JAK inhibitors producing significant response in myelofibrosis patients 2Health News:JAK inhibitors producing significant response in myelofibrosis patients 3Health News:AgriLife researchers find way to cut food-irradiation levels by half 2Health News:AgriLife researchers find way to cut food-irradiation levels by half 3Health News:AgriLife researchers find way to cut food-irradiation levels by half 4Health News:Gene Therapy Corrected Rare Bleeding Disorder: Study 2Health News:Gene Therapy Corrected Rare Bleeding Disorder: Study 3Health News:New Blood Thinner May Help Fight Dangerous Leg Clots 2Health News:New Blood Thinner May Help Fight Dangerous Leg Clots 3Health News:UIC researcher unveils new approach to blocking malaria transmission 2
ApolipoproteinA-1 & B Calibrator...
CRP Calibrator...
Fructosamine controls level 3...
Drug controls sera available in three levels for the control of accuracy and percision for up to 18 analytes...
Medicine Products: